Skip to main navigation

Top Menu

About Us
Our Science
Pipeline
Partnering
Investors & Media
Careers
Contact

Investors & Media

Press Releases

Year

Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea

Sep 21, 2016

Entasis Presents Data Supporting the Potential Clinical Utility of ETX2514, a Next-generation Beta-lactamase Inhibitor, at ASM Microbe 2016

Jun 28, 2016

Entasis to Present Preclinical Data on ETX2514, a Next-Generation Beta-lactamase Inhibitor, at ASM Microbe 2016

Jun 15, 2016

Entasis Announces $50 Million Series B Financing led by Clarus

Apr 04, 2016

Entasis Announces Appointments to its Scientific and Clinical Advisory Board

Dec 15, 2015

Entasis Appoints Robin David Isaacs as Chief Medical Officer

Jul 15, 2015

Entasis Debuts with a Portfolio of Drug Candidates to Treat Serious Drug-resistant Bacterial Infections

Jul 01, 2015

AstraZeneca to create stand-alone company for small molecule early stage antibiotic R&D

Feb 26, 2015

ETX0914 (AZD0914) designated a Qualified Infectious Disease Product (QIDP) and given Fast Track status by US FDA

Jun 03, 2014

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Current page 7

Displaying 61 - 69 of 69

Toolkit

Print page
RSS Feeds
Email Alerts
Search

Investor Relations

Corporate Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
SEC Filings
Corporate Governance
Investor Resources

"Antibiotic resistance is a worldwide problem that is constantly growing. New forms of resistance can spread quickly and across continents. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections."

— Ruben Tommasi, Chief Scientific Officer

©2020 Entasis Therapeutics Inc.

Terms of Use | Privacy Policy